Syon Capital LLC Acquires Shares of 11,134 Moderna, Inc. (NASDAQ:MRNA)

Syon Capital LLC purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 11,134 shares of the company's stock, valued at approximately $463,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Allworth Financial LP lifted its stake in Moderna by 17.3% during the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock worth $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. lifted its stake in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock worth $416,000 after purchasing an additional 297 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in Moderna by 0.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after purchasing an additional 345 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Moderna by 39.1% in the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock valued at $53,000 after acquiring an additional 356 shares during the last quarter. Finally, New Insight Wealth Advisors grew its position in Moderna by 4.4% during the 4th quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after acquiring an additional 358 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MRNA shares. UBS Group cut their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a report on Wednesday, February 19th. The Goldman Sachs Group cut Moderna from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Barclays cut Moderna from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Morgan Stanley reduced their price target on Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. Finally, Berenberg Bank upped their price target on Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $58.70.

Moderna Price Performance

Shares of NASDAQ:MRNA traded up $0.24 during mid-day trading on Monday, reaching $27.46. 5,752,053 shares of the company traded hands, compared to its average volume of 7,357,350. The company's 50 day moving average price is $30.19 and its 200-day moving average price is $38.37. The firm has a market cap of $10.62 billion, a PE ratio of -2.96 and a beta of 2.23. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.